Evan Loh
Net Worth
Last updated:
What is Evan Loh net worth?
The estimated net worth of Dr. Evan Loh is at least $12,219,216 as of 9 Aug 2023. He owns shares worth $13,800 as insider, has earned $1,665,416 from insider trading and has received compensation worth at least $10,540,000 in Paratek Pharmaceuticals, Inc. and Eiger BioPharmaceuticals, Inc..
What is the salary of Evan Loh?
Dr. Evan Loh salary is $1,030,000 per year as Chief Executive Officer & Director in Paratek Pharmaceuticals, Inc.. He also receives $60,000 as Chief Executive Officer of Paratek Pharmaceuticals & Director in Eiger BioPharmaceuticals, Inc..
How old is Evan Loh?
Dr. Evan Loh is 66 years old, born in 1959.
What stocks does Evan Loh currently own?
As insider, Dr. Evan Loh owns shares in 2 companies:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Paratek Pharmaceuticals, Inc. (PRTK) | Chief Executive Officer & Director | 1,327,981 | $0 | $0 |
| Eiger BioPharmaceuticals, Inc. (EIGR) | Chief Executive Officer of Paratek Pharmaceuticals & Director | 8,000 | $1.73 | $13,800 |
What does Paratek Pharmaceuticals, Inc. do?
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a tetracycline designed for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and contract with Biomedical Advanced Research and Development Authority to support the development of NUZYRA for the treatment of pulmonary anthrax. In addition, it has license agreement with Tetraphase Pharmaceuticals, Inc. to develop, import, and sell the XERAVATM product, which is used for the treatment of complicated intra-abdominal infections caused by bacteria. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts.
What does Eiger BioPharmaceuticals, Inc. do?
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California.
Evan Loh insider trading
Paratek Pharmaceuticals, Inc.
Dr. Evan Loh has made 27 insider trades between 2015-2023, according to the Form 4 filled with the SEC. Most recently he sold 48,967 units of PRTK stock worth $107,727 on 9 Aug 2023.
The largest trade he's ever made was exercising 61,919 units of PRTK stock on 13 Dec 2022. As of 9 Aug 2023 he still owns at least 1,327,981 units of PRTK stock.
Eiger BioPharmaceuticals, Inc.
Dr. Evan Loh has made only one insider trade in 2021, according to the Form 4 filled with the SEC. He sold 2,000 units of EIGR stock on 15 Mar 2021.
As of 9 Aug 2023 he still owns at least 8,000 units of EIGR stock.
Paratek Pharmaceuticals key executives
Paratek Pharmaceuticals, Inc. executives and other stock owners filed with the SEC:
- Dr. Evan Loh (66) Chief Executive Officer & Director
- Mr. Adam Woodrow (58) Pres & Chief Commercial Officer
- Mr. Michael F. Bigham CPA, CPA, M.B.A., MBA (67) Executive Chairman